A Comparison of the Frequencies of Medical Therapies for Overactive Bladder in Men and Women: Analysis of More Than 7.2 Million Aging Patients

European Urology

Volumn 57, Issue 4, 2010, Pages 586-591

  Helfand, Brian T ^a   Evans, R Mark ^b   McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b AMERICAN MEDICAL ASSOCIATION   (United States)

Author keywords

Anticholinergic therapy; Men; overactive; Urinary bladder; Women

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE; AGED; AGING; ARTICLE; COMPARATIVE STUDY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PREVALENCE; PRIORITY JOURNAL; SYMPTOM;

AGE DISTRIBUTION; AGE FACTORS; AGED; AGING; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHI-SQUARE DISTRIBUTION; CHOLINERGIC ANTAGONISTS; DATABASES AS TOPIC; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HEALTHCARE DISPARITIES; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; SEX DISTRIBUTION; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER, OVERACTIVE;

EID: 77249114093     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.12.025     Document Type: Article

References (30)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
2. Gerber G.S., and Brendler C.B. Evaluation of the urologic patient: history, physical examination, and urinalysis. In: Wein A., Kavoussi L.R., Novick A.C., Partin A.W., and Peters C.A. (Eds). Campbell-Walsh urology. 9th ed. (2007), Saunders/Elsevier, Philadelphia, PA 81-110
3. Chapple C.R., Wein A.J., Abrams P., et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol 54 (2008) 563-569
4. Homma Y., Yamaguchi O., and Hayashi K. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 96 (2005) 1314-1318
5. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306-1315 discussion 1314-5
6. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., and Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
7. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
8. Temml C., Heidler S., Ponholzer A., and Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 48 (2005) 622-627
9. Cisternas M.G., Foreman A.J., Marshall T.S., Runken M.C., Kobashi K.C., and Seifeldin R. Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage. Curr Med Res Opin 25 (2009) 911-919
10. Coyne K.S., Zhou Z., Bhattacharyya S.K., Thompson C.L., Dhawan R., and Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 92 (2003) 948-954
11. Wagg A., Majumdar A., Toozs-Hobson P., Patel A.K., Chapple C.R., and Hill S. Current and future trends in the management of overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 18 (2007) 81-94
12. Kirby M., Artibani W., Cardozo L., et al. Overactive bladder: the importance of new guidance. Int J Clin Pract 60 (2006) 1263-1271
13. Yamaguchi O., Aikawa K., Shishido K., and Nomiya M. Place of overactive bladder in male lower urinary tract symptoms. World J Urol 27 (2009) 723-728
14. Ignjatovic I. Symptoms and urodynamics after unsuccessful transurethral prostatectomy. Int Urol Nephrol 32 (2001) 655-658
15. Lee J.Y., Kim H.W., Lee S.J., Koh J.S., Suh H.J., and Chancellor M.B. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
16. Abrams P., Kaplan S., De Koning Gans H.J., and Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 (2006) 999-1004 discussion 1004
17. Roehrborn C.G., Abrams P., Rovner E.S., Kaplan S.A., Herschorn S., and Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 97 (2006) 1003-1006
18. Kaplan S.A., Roehrborn C.G., Chancellor M., Carlsson M., Bavendam T., and Guan Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 102 (2008) 1133-1139
19. Irwin D.E., Milsom I., Reilly K., et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med 5 (2008) 2904-2910
20. Andersson K.E., and Pehrson R. CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs 63 (2003) 2595-2611
21. Lawrence J.M., Lukacz E.S., Liu I.L., Nager C.W., and Luber K.M. Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente continence associated risk epidemiology study. Diabetes Care 30 (2007) 2536-2541
22. Wagg A.S., Cardozo L., Chapple C., et al. Overactive bladder syndrome in older people. BJU Int 99 (2007) 502-509
23. Hu T.W., and Wagner T.H. Economic considerations in overactive bladder. Am J Manag Care 6 suppl (2000) S591-S598
24. Greenland J.E., and Brading A.F. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 165 (2001) 245-248
25. Harrison S.C., Hunnam G.R., Farman P., Ferguson D.R., and Doyle P.T. Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 60 (1987) 519-522
26. Athanasopoulos A., Gyftopoulos K., Giannitsas K., Fisfis J., Perimenis P., and Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169 (2003) 2253-2256
27. Kaplan S.A., Walmsley K., and Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174 (2005) 2273-2275 discussion 2275-6
28. Chapple C.R., and Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49 (2006) 651-659
29. D'Souza A.O., Smith M.J., Miller L.A., Doyle J., and Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 14 (2008) 291-301
30. Donaldson M.M., Thompson J.R., Matthews R.J., Dallosso H.M., and McGrother C.W. The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3-year prospective cohort study. Neurourol Urodyn 25 (2006) 709-716